A recent study published in the Journal of Immunology found that individuals with thymoma-associated myasthenia gravis (MG) who have germinal centers in their thymic tissue may have a worse prognosis.
Among patients who did not receive prednisolone before thymectomy (surgery to remove the thymus), those with germinal centers were less likely to achieve minimal manifestation of disease status, which describes when MG has little to no impact on daily life. However, the authors observed no significant differences in how likely these patients were to achieve pharmacological remission, or how likely patients with germinal centers who received prednisolone were to reach minimal manifestation status.
Germinal centers are specialized structures that form in the thymus and other lymphoid organs. They are a key site for B cell expansion and antibody production. While germinal centers are linked with acetylcholine receptor (AChR) antibody production and thymoma-associated MG, their role in prognosis is less clear.
The study included 111 patients, 36.9% of whom were classified as germinal center-positive. The study defined minimal manifestations as not having functional limitations other than muscle weakness. Participants achieved pharmacological remission if they had no symptoms of MG for at least one year without receiving cholinesterase inhibitors.
Read more about MG prognosis
Overall, 56.1% of germinal center-positive patients had a Myasthenia Gravis Foundation of America classification of at least III, compared with 30.0% of germinal-center negative patients.
Germinal center-positive individuals were also significantly younger than germinal center-negative patients. Furthermore, after surgery, levels of AChR antibodies were higher among those classified as germinal center-positive.
Participants who received prednisolone before undergoing thymectomy had a significantly lower number of germinal centers. This may explain why the researchers observed no significant relationships in the overall study population.
These findings align with previous studies suggesting that germinal centers in thymomas may be linked with earlier-onset, more active MG. A limitation of the study, though, is that many patients were excluded because their biopsy samples prevented germinal center analysis.
“Medications for MG treatment lacked standardized protocols and [were] highly individualized, limiting our ability to precisely quantify treatment-related confounding,” the authors noted. “Knowledge concerning the risk factors for poor prognosis is needed for adequate clinical care and to plan for future treatment.”
Sign up here to get the latest news, perspectives, and information about MG sent directly to your inbox. Registration is free and only takes a minute.
